NEO : CYBN | NYSE American : CYBN

On a Mission to revolutionize mental healthcare

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Request Investor Info

This form collects information we will use to send you information on market news and insightful information for your portfolio. We will not share or sell your personal information. You can unsubscribe at any time.

As seen on BNN Bloomberg:

Why Invest?

  • Over C$120M raised to date. Well-funded to progress clinical trials, M&A, and IP strategies
  • Multiple active drug programs targeting Major Depressive Disorder, Alcohol Use Disorder, Anxiety Disorders, and other Psychiatric Disorders
  • Robust patent portfolio covering three patent families focused on Novel psychedelic compounds, Integration of delivery platforms, and Methods of use in psychiatric indications
  • A team with 30+ years of experience in the healthcare sector

Learn More about Cybin

Request Investor Info!

Certain statements regarding psilocybin have not been evaluated by the Food and Drug Administration, Health Canada, or other similar regulatory authorities, nor has the efficacy of psilocybin been confirmed by approved research. There is no assurance that psilocybin can be used to diagnose, treat, cure or prevent any disease or condition and robust scientific research and clinical trials are needed.